Wee1
Wee1 is a tyrosine kinase that is a crucial component of the G2–M cell cycle checkpoint that prevents entry into mitosis in response to cellular DNA damage. Before mitosis, CDK1 is maintained in an inactive state by WEE1 through phosphorylation of CDK1 at tyrosine 15, and then CDK1 is phosphorylated at threonine 14 by myelin transcription factor (MYT1) [6–8]. Therefore, WEE1 acts as a negative regulator of entry into mitosis at the G2–M transition by protecting the nucleus from cyclin B complexed with CDK1 activated in the cytoplasm. The transcriptional synthesis and activity of WEE1 increases during S and G2 phases, and decreases at M phase when it is hyper-phosphorylated. As the cell approaches the G2–M transition, in the absence of substantive DNA damage, polo-like kinase 1 (PLK1) phosphorylates WEE1, which targets WEE1 for degradation via the ubiquitin ligase complex.
ATR phosphorylates and activates CHK1, which then phosphorylates WEE1 and CDC25C, thereby both activating WEE1 kinase activity and inactivating CDC25C phosphatase activity. Then, WEE1 phosphorylates and inactivates the CDK1–cyclin B complex on tyrosine 15, resulting in cell-cycle arrest in G2, allowing time for DNA repair. Inhibition of WEE1 kinase activity and removal of the G2–M checkpoint is an attractive strategy to drive cancer cells to enter into unscheduled mitosis and ultimately undergo cell death via mitotic catastrophe. Taken together, these support an important role for WEE1 in both DNA repair and the maintenance of genomic integrity, and that WEE1 may be a viable therapeutic target in cancer therapy.
References
1.Matheson CJ,et al. Trends Pharmacol Sci. 2016;37(10):872–881.
ATR phosphorylates and activates CHK1, which then phosphorylates WEE1 and CDC25C, thereby both activating WEE1 kinase activity and inactivating CDC25C phosphatase activity. Then, WEE1 phosphorylates and inactivates the CDK1–cyclin B complex on tyrosine 15, resulting in cell-cycle arrest in G2, allowing time for DNA repair. Inhibition of WEE1 kinase activity and removal of the G2–M checkpoint is an attractive strategy to drive cancer cells to enter into unscheduled mitosis and ultimately undergo cell death via mitotic catastrophe. Taken together, these support an important role for WEE1 in both DNA repair and the maintenance of genomic integrity, and that WEE1 may be a viable therapeutic target in cancer therapy.
References
1.Matheson CJ,et al. Trends Pharmacol Sci. 2016;37(10):872–881.
Cell Cycle/DNA Damage
ABC(12)
AChR(104)
Antifolate(12)
ATM/ATR(26)
Aurora Kinase(51)
CLK(15)
c-Myc(22)
DHFR(16)
DNA Alkylator(34)
DNA gyrase(11)
DNA Repair Protein(21)
DNA/RNA Synthesis(187)
DNA-PK(15)
GPR(97)
HDAC(152)
Hec1/Nek2(9)
Integrin(77)
LIM Kinase (LIMK)(7)
Mps1/TTK(2)
Nucleoside Antimetabolite/Analog(48)
Other Targets(4)
PAK(13)
PARP(67)
PLK(26)
Potassium Channel(146)
RAD51(1)
Rho(16)
ROCK(42)
Telomerase(12)
Topoisomerase(88)
Wee1(7)
Wee1
-
Debio-0123
产品货号 : M37689
cas no: 2243882-74-6
WEE1-IN-5 是一种有效的 WEE1 抑制剂,IC50 为 0.8 nM。WEE1-IN-5 可抑制磷酸化 CDC2。WEE1-IN-5 消除 G2 检查点,增加癌细胞对 DNA 损伤剂 Carboplatin (HY-17393) 的敏感性。WEE1-IN-5 可用于抗癌研究。 -
RP-6306
产品货号 : M35485
cas no: 2719793-90-3
RP-6306 ((S)-RP-6306) 是一种有效的、选择性的、具有口服活性的 PKMYT1 抑制剂,IC50 为 14 nM。RP-6306 在细胞结合测定中表现出比其他激酶更高的选择性。RP-6306 具有抗癌活性。 -
PD 407824
产品货号 : M33454
cas no: 622864-54-4
PD 407824 是一个检查点激酶 Chk1 和 WEE1 抑制剂,IC50分别为 47 和 97 nM。PD 407824 是一种化学 BMP 敏化剂,可提高细胞对亚阈值量的 BMP4 的敏感性。 -
ZN-c3
产品货号 : M28820
cas no: 2376146-48-2
ZN-c3 是一种有效的选择性 Wee1 抑制剂,具有平衡的效力、ADME 和药代动力学特性。 -
JUN76288
产品货号 : M24035
cas no: 2272976-28-8
JUN76288 是一种有效的 Wee1 激酶抑制剂,IC50 小于 10 nM。它治疗癌症和其他增殖性疾病。